What you need to know about summer skin care, according to dermatologists
We independently evaluate the products we review. When you buy via links on our site, we may receive compensation. Read more about how we vet products and deals .
Your skin has special needs in summer, but there are plenty of products that can give it the TLC it needs. (Getty)
Summer is just around the corner, and as a beauty editor, I've already started transitioning my daily regimen to products that can better support my skin as warmer temperatures hit. I've talked with countless dermatologists over the years, so I know that what my face requires when it's 90°F and humid is a lot different than what it needs when it's a frigid, wind-whipping -5°.
But the best summer skin care isn't solely about finding the right products, says Los Angeles-based cosmetic dermatologist Dr. Ava Shamban. "To avoid skin irritation in the hot summer months, you should wear loose-fitting clothing made with natural fibers whenever you can. And, if you're exercising in nylon and spandex, you should remove your workout clothes as quickly as possible and shower to keep skin from developing rashes and infections." Shamban also advises clients to track the UV index and avoid being outside in direct sunlight when it's high. "If you have to be in the sun, wear a hat, sunglasses and sun-protective clothing," she explains. To best support summer skin at home, Shamban says you should trade long, hot baths for shorter, more tepid showers and focus on hydration — not just via ample H2O intake, but by eating more fresh fruits and vegetables with high water content.
As for makeup, she says, "Lay off the heavy, full-face foundation in hot summer months, which can trap bacteria and clog pores. Instead, opt for lighter noncomedogenic makeup options — there are now so many multi-tasking products that can serve as a primer and a light lotion foundation with full SPF that can be skin saviors in summer."
Below, I asked Shamban and Dr. Dara Spearman, a board-certified dermatologist, for the products they recommend most as the thermostat rises.
For cleansing summer skin
The first rule of summer skin care? Getting serious about clearing your face of accumulated grime after a hot day. "You should always use a gentle cleanser to wash away debris, sweat and oil," says Spearman. "Also, I recommend showering with cooler or even cold water to keep the skin cool and promote better blood flow — hot showers tend to dry out the skin even more."
Amazon EltaMD Oil-In-Gel Facial Cleanser
"This is a highly effective face wash with an advanced cleansing complex," says Shamban. "What I like about it is it's tough enough to remove waterproof sunscreen and heavy makeup while remaining gentle on the skin. It's a silky oil that morphs into an emulsion with pumpkin enzymes and vitamin E, so it also exfoliates and provides antioxidant support." $33 at Walmart
Explore More Buying Options $37 at Amazon$37 at Dermstore
For exfoliating summer skin
"One of the best ways to care for your skin in summer is to exfoliate often to remove dead skin cells," says Spearman. Adds Shamban: "Exfoliating also helps to ensure that the actives and antioxidants in your skin care can penetrate and that excess sebum and bacteria are not trapped on the surface, causing blemishes."
Amazon Paula's Choice Skin Perfecting Exfoliant
Spearman's pick for best warm-weather exfoliator is this internet-famous potion by Paula's Choice: "I recommend this exfoliant often because it is great for all skin types. It is great for cleaning clogged pores and targeting blackheads," she says. "And if you're prone to breakouts, this is a good add to your summer regimen because sebum buildup is more likely to occur due to excess sweat and oil."
It's not just Spearman who's enamored with this product — more than 77,000 five-star Amazon reviewers agree and have made it a top-seller. $14 at Amazon
Amazon Tatcha The Rice Polish Classic
In the summer, Shamban recommends swapping chemical exfoliants for gentler physical or enzymatic versions. "Chemical exfoliants may cause sun reactions, irritation, inflammation or interfere with skin barrier function," she says. "I tell clients to look for versions with rice enzymes or natural fruit enzymes."
This beloved rice polish is a longtime favorite of celebrities and skin-care experts alike. Meghan Markle once told Allure that she loves it because "it just sort of foams on your face and gives you a really subtle exfoliation."
Every beauty editor I know uses this to cleanse their skin at night — it's especially good for those of us who are over 50. $68 at Amazon
For moisturizing summer skin
"Always always moisturize," says Spearman. "Summertime can cause dry skin due to dehydration from sun exposure and things like the sand and ocean water, so it's important to keep the skin hydrated."
SkinCeuticals SkinCeuticals Daily Moisture
Spearman says this SkinCeuticals moisturizer is "great for all skin types and it's especially good for oilier skin types, provides hydration but is light weight so it can be layered with other products like makeup and is great for minimizing pores too." $78 at Skinceuticals
For protecting summer skin
"SPF is definitely essential and should be used regularly," Spearman says. "If you are going to be in the sun all day or in the pool/ocean, it's of course important to reapply." Most experts I've spoken with recommend setting a timer and slathering on a fresh coat of sunscreen every hour.
Related: The best sunscreens for sensitive skin
Devices for summer skin
If you'd been considering picking up an LED mask, now may be the ideal time — experts like Shamban recommend red-light masks and devices specifically for use on summer skin. "Red light therapy is a great treatment to help reduce inflammation, stimulate collagen production and enhance wound healing — all beneficial for repairing sun-damaged skin throughout the summer," she says.
Omnilux Omnilux Contour LED Face Mask
I tested Omnilux's Light Therapy Mask for six weeks last summer, and within days, my sun-damaged skin looked tighter, particularly around my cheekbones. Within a month, the wrinkles on my forehead appeared less deep, and so did those around my mouth. My complexion was clearer overall. The results were subtle but apparent — my pores were smaller, my face looked softer and my skin had a bit of a glow. My conclusion: With consistent use, the Omnilux mask works — so well that we named it the best LED face mask of the year. $395 at Omnilux
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
37 minutes ago
- Business Wire
Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions
NEW YORK--(BUSINESS WIRE)-- Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Ontellus, a leading provider of health records retrieval and claims intelligence from Aquiline, a private investment firm specializing in financial services and technology and Capstreet, a Houston-based lower middle market private equity firm. With this acquisition, Ontellus will join Datavant to deliver an integrated, digital-first platform that connects those with health records to those who need them easily, quickly and securely. In addition to driving value to providers, freeing up more of their time to focus on patient care, this acquisition will transform the experience for requesters from a largely manual and time consuming process to a more efficient, digital process. The combined organization will reduce administrative burden for Datavant's network of over 80,000 health care providers, clinics, hospitals and health system partners, who routinely manage requests for health records—vital for life insurance underwriting, injury claims, and legal case work. Today, the record retrieval process remains highly fragmented, with inconsistent workflows, procedures, and data formats across thousands of organizations. By joining forces, Datavant and Ontellus reaffirm their shared commitment to simplify this complexity and improve access to records to ensure that confidential health records are digitized in a secure and timely manner to authorized parties. 'Moving health data securely and compliantly from where it sits to where it needs to be in the right format to authorized users is one of the industry's biggest challenges,' said Datavant CEO Kyle Armbrester. 'In addition to driving value to our health care providers, freeing up more of their time to focus on patient care, this acquisition will transform the experience for requesters from a largely manual and time consuming process to a more efficient, digital process that leverages Datavant's deep expertise in privacy preservation and compliance. We are delighted to welcome Ontellus' world-class team and work with them to further transform the health data request process for all of our customers.' Ontellus has digitized its records retrieval business into a nationwide platform through which record requestors have direct access to providers. Additionally, through its canvassing services, Ontellus delivers detailed claimant treatment timelines to validate claims or uncover preexisting conditions, helping customers reduce unnecessary and costly claims exposure. Datavant will join Ontellus' capabilities with its own digital connectivity capabilities to create a highly tech-enabled integrated platform offering to better serve all customers. Ontellus CEO, Vince Cole, will join Datavant's Executive Leadership Team, reporting directly to Kyle Armbrester, Datavant CEO. 'By combining Ontellus' industry-leading request fulfillment infrastructure with Datavant's advanced connectivity and data exchange capabilities, we're enabling faster, more precise access to critical health information—not only for healthcare providers, but also for legal and insurance professionals who rely on timely, accurate data to support claims and compliance. We are deeply grateful to our investor partners, Aquiline Capital Partners and The Capstreet Group, whose strategic guidance and resources have powered our growth and product innovation,' said Vince Cole, CEO of Ontellus. Houlihan Lokey served as buyside financial advisor to Datavant, assisting in evaluating and negotiating the acquisition. Harris Williams is the sell-side advisor to Ontellus, representing the company in its pending sale to Datavant. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 80,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Ontellus Ontellus empowers insurance carriers, self-insured corporations and law firms to reduce costs, make informed decisions and accelerate claims resolution. As one of the nation's largest, privately held data retrieval and claims intelligence providers, Ontellus leverages decades of experience and cutting-edge technology to deliver impactful products and client-centric services with industry-leading turnaround times. For more information, visit
Yahoo
an hour ago
- Yahoo
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention. Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston Convention & Exhibition Center The Company's lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The Company is currently conducting a Phase 2 clinical study SKNJCT-003 in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President (610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
Family Ties May Shape Hashimoto Thyroiditis Risk
The odds of developing Hashimoto thyroiditis (HT) were significantly elevated in first-, second-, and third-degree relatives of patients with HT, with female relatives having a disproportionately higher likelihood. Of note, the odds of developing HT were elevated among spouses of patients. METHODOLOGY: Relatives of patients with HT are at an increased risk for HT; however, studies have primarily focused on first-degree relatives and often employed very small sample sizes. Researchers conducted a retrospective case-control study using genealogical and medical data from a Utah-based database (1996-2021) to estimate the risk for HT in relatives across various degrees of relatedness. They included 92,405 adult HT probands (73% women; 96% White individuals) and 184,810 matched control individuals, along with 2,960,650 first-, second-, and third-degree relatives of HT probands and 5,730,159 relatives of control individuals. TAKEAWAY: Relatives of patients with HT were at an increased risk for the condition, with the highest odds observed for first-degree relatives (odds ratio [OR], 1.77; 95% CI, 1.74-1.80), followed by second-degree (OR, 1.23; 95% CI, 1.22-1.27) and third-degree (OR, 1.11; 95% CI, 1.10-1.12) relatives. The risk for HT was an additional 2.2- to 2.6-fold higher in female relatives of patients with HT than overall estimates, across all degrees of relatedness. Among first-degree relatives, sons of men with HT had a markedly elevated risk for HT (OR, 2.36; 95% CI, 2.10-2.65). Wives of men with HT and husbands of women with HT were at an increased likelihood of developing HT, suggesting the effect of a shared environment. IN PRACTICE: 'These findings also have clinical implications, as understanding familial clustering of HT can help healthcare providers identify individuals at higher risk, especially those with affected FDRs [first-degree relatives]. This knowledge could lead to earlier monitoring and intervention, improving disease management,' the authors of the study wrote. SOURCE: This study was led by Melissa Bujnis, PhD, Department of Human Genetics, University of Utah, Salt Lake City. It was published online in The Journal of Clinical Endocrinology & Metabolism . LIMITATIONS: Reliance on diagnostic codes may have introduced misclassification bias, particularly in cases of transient hypothyroidism or misdiagnosed HT. Variations in diagnostic practices across clinics may have introduced heterogeneity in the sample. Individuals with a family history of HT might be more likely to receive diagnosis or seek medical attention, potentially introducing ascertainment bias. DISCLOSURES: Partial support for the datasets in the database was provided by the University of Utah, Huntsman Cancer Institute, National Institutes of Health (NIH). This study received support from NIH, NCRR, and Utah Department of Health and Human Services and the University of Utah. The authors reported no relevant conflicts of interest.